Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer

Completed

Conditions studied: Cervical Cancer

In brief

The investigators hope to learn whether perfusion CT is a useful way to assess primary cervical tumor microenvironment and whether there is a relationship between pretreatment perfusion CT measurements and primary cervical tumor size, lymph node involvement (as assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT (FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy FDG-PET/CT).

Key facts

Study ID

NCT01805141

Run by

Stanford University

People needed

24

Starts

2013-08-01

Expected to finish

2018-10-04

Last updated by the study team

2018-10-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >18 years old
• with biopsy-proven squamous, adenocarcinoma or adenosquamous cervical cancer
• no history of prior pelvic radiation and should be able to receive chemoradiation
• non-pregnant women who have not previously undergone a hysterectomy, as that would have removed the cervix.
• able to give informed consent

You may not qualify if…

• Subjects whose tumors are not FDG avid on the pre-therapy PET.
• Allergy or inability to receive iodinated CT contrast

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.